UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector
To curb state-level Medicaid expenditures, the bill gradually limits the use of 'provider taxes' as a revenue source. However, it also allocates $50 billion in funding to support rural hospitals impacted by these cuts. While insurers like UnitedHealth and Humana Inc. HUM may encounter short-term pressure from shrinking Medicaid rolls, they could ultimately benefit as displaced members shift toward private coverage options.
UnitedHealth's Medicaid membership declined 4% in 2023, 5.2% in 2024, and 1.4% in the first quarter of 2025. The proposed elimination of ACA marketplace tax credits will likely propel more people into employer-sponsored plans. Meanwhile, Medicare Advantage may gain traction, as seniors grapple with increased out-of-pocket expenses due to rollbacks in Medicare Savings Programs. UnitedHealth's Medicare Advantage enrollment rose by 8.3% in 2023, 1.9% in 2024, and 6.3% in the first quarter of 2025.
Another major development shook the market as Centene Corporation CNC, a major Medicaid player, withdrew its 2025 earnings guidance late Tuesday, citing unexpected enrollment shifts and higher medical costs. The move, mirroring UnitedHealth's earlier decision, rattled the managed care sector. Centene shares witnessed massive declines following the news, and peers like UnitedHealth and Humana followed suit.
Centene shares plummeted 41.2% following the announcement, dragging down peers: UnitedHealth and Humana dropped 5.4% and 5.1%, respectively, despite broader market gains driven by tech strength and encouraging jobs data.
Price Performance Comparison – UNH, HUM & CNC
Image Source: Zacks Investment Research
UnitedHealth's Valuation and Estimates
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 12.99, up from the industry average of 11.49. UNH currently carries a Value Score of A.
The Zacks Consensus Estimate for UnitedHealth's 2025 earnings is pegged at $22.07 per share, implying a 20.2% drop from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Humana Inc. (HUM): Free Stock Analysis Report
Centene Corporation (CNC): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
26 minutes ago
- Globe and Mail
Iovance Biotherapeutics CFO Resignation and Interim Appointment
Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Iovance Biotherapeutics ( (IOVA)) just unveiled an announcement. On June 30, 2025, Iovance Biotherapeutics announced the resignation of Jean-Marc Bellemin as Chief Financial Officer, effective immediately, with Matthew W. Rosinack stepping in as interim Principal Financial Officer and Principal Accounting Officer. Rosinack, who has extensive experience in finance roles at various biotechnology and medical device companies, has been with Iovance since September 2021 and will temporarily fill the role as the company navigates this transition. The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page. Spark's Take on IOVA Stock According to Spark, TipRanks' AI Analyst, IOVA is a Neutral. Iovance Biotherapeutics' stock score reflects its current growth phase marked by significant revenue increases and strong equity, offset by ongoing losses and cash flow challenges. The technical indicators suggest bearish momentum, while mixed earnings call sentiments and recent corporate events add moderate risk. The valuation is impacted by negative earnings, typical for a company investing heavily in growth. To see Spark's full report on IOVA stock, click here. More about Iovance Biotherapeutics Average Trading Volume: 13,697,268 Technical Sentiment Signal: Sell Current Market Cap: $581M See more data about IOVA stock on TipRanks' Stock Analysis page. Disclaimer & Disclosure Report an Issue
Globe and Mail
27 minutes ago
- Globe and Mail
Point of Care Diagnostics Market to Hit USD 22.63 Billion by 2029 with 8.5% CAGR
"The major players operating in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK)" Browse 786 market data Tables and 64 Figures spread through 577 Pages and in-depth TOC on "Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (TB, HAI, STD), Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx (RT-PCR, INAAT)), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2029 The global point of care diagnostics market valued at US$ 14.26 billion in 2023, is forecasted to grow at a robust CAGR of 8.5%, reaching US$ 15.05 billion in 2024 and an impressive US$ 22.63 billion by 2029. The growing prevalence of chronic diseases, such as diabetes has necessitated a need for routine monitoring with early and timely detection. Since these conditions need to be constantly monitored, the demand for quick, effective, and appropriate testing methods have expanded. For instance, increasing demand for POC diagnostics like glucose monitoring products is because of the easy, quick results, which patients get, helping them to take care of the disease and make an early intervention. Government initiatives promoting POC testing, including investments in health care innovation are also contributing to increased market growth. Browse in-depth TOC on " Point of Care Diagnostics Market" 778 - Tables 59 - Figures 564 - Pages Advances such as miniaturized, transportable diagnostic devices, which present laboratory-quality findings outside of health care settings, represent a leading technological shift within the point of care diagnostics market. These small devices, largely based on new, advanced forms of biosensors, will deliver testing in real-time with higher degrees of accuracy at a faster cost and are sure to revolutionize health care. These will affect health care primarily in areas related to conditions whose management requires routine monitoring, which includes diabetes and infectious diseases. As these devices continue to become increasingly accessible and affordable, they are going to create new business opportunities in home healthcare, telemedicine, and emergency care, and accelerating adoption across all patient populations. Based on mode of purchase, the point of care diagnostics market is segmented into OTC testing products and prescription-based testing products. The prescription-based testing products segment is expected to be the fastest-growing segment in the market. Stricter regulatory standards, focus on quality, and healthcare providers' recommendation for the test are among the key factors that contribute to the high growth rate of prescription-based testing products. These products need to be subjected to very strict quality and safety measures, which improves the credibility and reliability of these products. Healthcare providers actively engage in using these tests in a way that they produce the best clinical results. With the focus on early detection, prescription-based testing continues to experience strong market growth, which is driving its high growth rate. Categorized by technology, the point of care diagnostics market is segmented into immunoassays, molecular diagnostics, and biochemistry. The biochemistry segment is the dominant technology segment because these tests can quickly, reliably, and cost-effectively provide the results for conditions such as diabetes and pregnancy & fertility testing. Real-time results offered by biochemistry-based tests, like glucose meters are easy to use and well-suited both for homecare and emergency applications. Such technologies assure on-site diagnosis without the complexity of expensive laboratory infrastructure in a point of care environment. With such convenience, accessibility, and ability to cater to increasing demands for rapid and efficient testing, biochemistry technology continues to lead the market. The key players in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK), Trinity Biotech (Ireland), Werfen (US), Nova Biomedical (US), SEKISUI Diagnostics (US), and Boditech Med Inc. (South Korea). The market players have adopted various strategies such as development of advanced products, partnerships, expansions, and acquisitions to strengthen their position in the point of care diagnostics market. The organic and inorganic strategies have helped the market players expand globally by providing advanced point of care tests. Abbott is a key player in the point of care diagnostics market, offering a comprehensive range of diagnostic solutions such as blood screening, immunoassays, and clinical chemistry systems. The company's strong global presence allows it to expand its reach in both established and emerging markets. Abbott stays ahead of the competition through continuous innovation and a focus on research and development. By introducing new products and securing important regulatory approvals, Abbott has solidified its leadership. For example, in April 2024, the company's i-STAT TBI cartridge received FDA clearance to be used with whole blood, further strengthening its position in the POC diagnostics market. F. Hoffmann-La Roche Ltd is a major player in the global point of care diagnostics market, having gained a reputation as a leader in the diagnostics market. Its extensive portfolio and global presence have enabled the company to maintain its competitive edge. Roche has an excellent direct and indirect distribution network across the world, which allows it to compensate for demand volatility in the various markets. Its strategic focus both on organic and inorganic growth strategies further strengthens the company's market presence. For instance, the cobas pulse system was launched by Roche in January 2022 as a connected point-of-care solution to be used with professional blood glucose monitoring only in certain CE Mark countries. All these strategies, along with its strong presence in the market, have given Roche further opportunities to enhance its position within the point of care diagnostics market. Siemens Healthineers AG is a leading company in the point of care diagnostics market, providing a broad range of products like clinical chemistry platforms, immunodiagnostics, and molecular diagnostic testing. The company is committed to expanding its portfolio through strategic acquisitions and innovations in order to respond to the changing needs of patients and healthcare providers. Moreover, Siemens Healthineers focuses on partnerships to further strengthen its position in the market. With a significant worldwide presence in over 70 countries, the group is poised well for growth in the POC diagnostics market. For more information, Inquire Now!
Globe and Mail
2 hours ago
- Globe and Mail
YFN Jewelry Brings Affordable Luxury to Life with Factory-Direct Gold and Custom Creations
In 2025, the definition of luxury is shifting. Consumers are no longer impressed by sky-high prices or legacy logos — they're looking for meaning, craftsmanship, and transparency. Enter YFN Jewelry, a brand that blends quality materials, thoughtful design, and personal storytelling — all without the luxury markup. As inflation and post-pandemic spending reshape consumer behavior, affordable luxury has become more than a buzzword; it's a demand. And YFN is meeting it head-on with factory-direct pricing, fast customization, and over 10,000 handcrafted jewelry options. Factory-Direct Pricing Without the Middleman Markup Most traditional jewelry retailers operate through multi-tiered supply chains — brands outsource design, manufacturing, and distribution, with each stage adding layers of cost. YFN takes a different approach. As a factory-direct brand, it controls the entire process in-house — from original design and material sourcing to production and fulfillment. This vertical integration allows YFN to price its products significantly lower than comparable offerings on the market. For example: A 14k gold birthstone necklace with custom engraving from a traditional luxury retailer might cost over $500. On YFN, a similar handcrafted version is available for $299 or less, with free personalization included. A 0.5 ct D-VVS1 lab-grown diamond cushion-cut solitaire engagement ring in 14k gold typically retails at $2000–3000 from mall jewelers. YFN offers comparable designs with the same stone quality and finish starting at $900. YFN doesn't cut corners — it cuts out the middlemen. The result is luxury you can see, feel, and afford. Quality Craftsmanship Meets Personal Expression Affordability doesn't mean compromise. YFN uses premium materials — 925 sterling silver, 10K/14K/18K solid gold, and ethically sourced gemstones, including lab-grown diamonds — to ensure each piece meets high standards of durability and brilliance. Every order is handcrafted by experienced artisans, with attention paid to gemstone setting, engraving precision, polishing, and structural finishing. Customization is a key part of the brand's value: customers can engrave names, initials, dates, or choose specific birthstones and symbolic elements to create a truly personal item. Unlike many brands that require weeks for custom orders, YFN completes most personalized jewelry within 7–10 business days — an impressive turnaround well below industry averages. A Vast Selection to Fit Every Style and Occasion YFN offers more than 10,000 products across 500+ themed collections, giving customers access to one of the most diverse and comprehensive jewelry selections available online. From understated classics to deeply personal statement pieces, there's something for everyone. Some of the brand's bestselling series include: Lab-Grown Diamond Engagement Rings – a modern choice for couples seeking ethical, sustainable, and high-quality stones without the traditional price tag. Initial Jewelry – minimalist necklaces and rings engraved with letters or monograms, perfect for gifting or layering. Birthstone Jewelry – meaningful pieces featuring the gem that represents your birth month or that of a loved one, ideal for birthdays, anniversaries, and mother-child keepsakes. Engraving Jewelry – fully personalized items with names, dates, coordinates, or short messages that carry personal significance. This breadth of themes allows YFN to meet both emotional and aesthetic needs—whether you're celebrating a milestone, remembering a loved one, or simply expressing your style. Meeting the Needs of a Value-Conscious Generation Today's consumers — especially Gen Z and millennials — care about where their money goes. They seek transparency, authenticity, and value. In fact, according to Shopify's 2025 consumer trend report, searches for 'affordable gold jewelry' have surged by over 30% year-over-year, while interest in 'custom gifts' has doubled since 2023. YFN Jewelry sits at the intersection of these trends: offering the aesthetic appeal of luxury with the integrity and personalization modern shoppers crave. The brand's direct-to-consumer model, ethical practices, and fast fulfillment create a seamless experience without the pressure or price tag of traditional retail. Luxury, Made for You At its core, YFN's mission is to make premium, personalized jewelry accessible to everyone — no matter the budget, the occasion, or the story behind the piece. Visit to explore their themed collections, experience custom design, and discover what affordable luxury truly looks like — made just for you.
